|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$82,119,756 |
|
|
Indirect Value
|
$12,961,771,173 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,043,890,929 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 34 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Director |
|
2006-08-14 |
4 |
B |
$4.05 |
$48,924 |
I/I |
12,080 |
1,535,999 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-11 |
4 |
B |
$10.94 |
$132,548 |
I/I |
12,120 |
3,033,182 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2005-03-23 |
4 |
B |
$4.96 |
$60,338 |
I/I |
12,166 |
25,718 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-10-31 |
4 |
S |
$11.70 |
$142,662 |
I/I |
(12,198) |
653,129 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-06-21 |
4 |
B |
$4.07 |
$49,776 |
I/I |
12,220 |
1,212,541 |
2.25 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2009-05-13 |
4 |
B |
$5.45 |
$67,015 |
I/I |
12,279 |
181,798 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-10 |
4 |
B |
$5.32 |
$65,400 |
I/I |
12,298 |
74,980 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-03 |
4 |
S |
$12.16 |
$149,579 |
I/I |
(12,300) |
528,661 |
0 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-05 |
4 |
S |
$8.11 |
$100,285 |
I/I |
(12,317) |
215,796 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-05 |
4 |
S |
$12.28 |
$151,769 |
I/I |
(12,355) |
1,030,107 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-12-06 |
4 |
S |
$12.35 |
$155,723 |
I/I |
(12,606) |
502,680 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-06-30 |
4 |
S |
$14.99 |
$188,998 |
I/I |
(12,606) |
288,286 |
0 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2007-01-25 |
4 |
B |
$6.00 |
$76,206 |
I/I |
12,701 |
625,292 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-03 |
4 |
B |
$5.71 |
$73,984 |
I/I |
12,952 |
22,971 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2010-09-21 |
4 |
S |
$14.94 |
$193,870 |
I/I |
(12,974) |
168,388 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2007-05-30 |
4 |
B |
$16.44 |
$216,097 |
I/I |
13,142 |
3,171,209 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-11-15 |
4 |
S |
$11.77 |
$155,580 |
I/I |
(13,213) |
550,546 |
0 |
- |
|
RDEA |
Ardea Biosciences Inc |
Director |
|
2010-04-06 |
4 |
B |
$20.00 |
$268,620 |
I/I |
13,431 |
83,467 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2010-06-08 |
4 |
B |
$11.92 |
$160,502 |
I/I |
13,431 |
255,252 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-10-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,542) |
94,049 |
|
- |
|
INCY |
Incyte Corp |
10% Owner |
|
2003-09-22 |
4 |
B |
$4.97 |
$67,614 |
I/I |
13,600 |
263,300 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-03 |
4 |
B |
$5.71 |
$78,057 |
I/I |
13,665 |
24,236 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-14 |
4 |
B |
$10.99 |
$150,254 |
I/I |
13,675 |
3,046,857 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-04 |
4 |
S |
$8.01 |
$115,265 |
I/I |
(13,809) |
86,069 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Director |
|
2010-09-28 |
4 |
B |
$2.45 |
$34,100 |
I/I |
13,916 |
1,242,773 |
2.25 |
- |
|
1397 Records found
|
|
Page 34 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|